New blood test pinpoints Parkinson’s disease through mitochondrial DNA damage

Researchers have developed a new blood test that measures mitochondrial DNA damage as a potential marker for Parkinson’s disease (PD). The study shows the test could aid in diagnosing PD and assessing responses to LRRK2 kinase inhibitors, which may help in reducing mitochondrial damage in PD patients.

Pharmaceutical Technology | Drug Development News & Views Updated DailyHome – Pharmaceutical Technology

Latest Issue Pharma Technology Focus Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read

September 27, 2024

Gilead spotlights its oncology work with first focused branding campaign

Gilead Sciences is well-known for its innovative HIV and hepatitis medications, but its profile is lower in oncology. The biopharma has been working to change

November 11, 2023

Novo Nordisk takes $816M writedown after Phase 3 fail in chronic kidney disease

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.